title: Early hematological toxicity of adjuvant perioperative intraportal and intravenous chemotherapy with fluorouracil, mitomycin and heparin in colorectal cancer. Swiss Group for Clinical Cancer Research.
abstract: BACKGROUND
  From 1987 to 1993 the Swiss Group for Clinical Cancer Research (SAKK) performed a randomized phase III adjuvant trial in patients with colorectal adenocarcinoma with the objective of comparing intraportal versus intravenous perioperative chemotherapy.
  
  
  METHODS
  Patients younger than 75 years had a curative en bloc resection of their cancer and were then randomized into three arms: 1. adjuvant perioperative portal liver infusion with fluorouracil, mitomycin and heparin, 2. adjuvant subclavian intravenous infusion with the same regimen and 3. no adjuvant treatment. The hematological toxicity was evaluated by hemoglobin determination and leucocyte and thrombocyte counting before and during ten days after surgery.
  
  
  RESULTS
  Hemoglobin showed a median decrease of 22% in the control group. This decrease is aggravated significantly by 3% through the chemotherapy. Leucocytes showed a median decrease of 7% in the control group. Perioperative chemotherapy caused a significantly higher median drop; 23% when given into the liver through the portal vein and 34% when given systemically through a subclavian catheter. Thrombocytes revealed a median decrease of 25% in the control group. Chemotherapy was not associated with a significant additional drop.
  
  
  CONCLUSIONS
  Adjuvant perioperative chemotherapy with fluorouracil, mitomycin and Heparin as given in this study is associated with a significant mild drop in hemoglobin and leucocytes during the first 10 postoperative days. If drug dose increases are planned in future trials the addition of hematopoietic growth factors might be considered.
authors.affiliation: SAKK, Bern, Switzerland.
authors.forename: W
authors.initials: W
authors.lastname: Weber
authors.forename: R
authors.initials: R
authors.lastname: Maibach
authors.forename: U
authors.initials: U
authors.lastname: Laffer
authors.forename: U
authors.initials: U
authors.lastname: Metzger
authors.forename: R
authors.initials: R
authors.lastname: Egeli
authors.forename: M
authors.initials: M
authors.lastname: Lorenz
authors.forename: P
authors.initials: P
authors.lastname: Aeberhard
authors.forename: V
authors.initials: V
authors.lastname: Dupont-Lampert
authors.forename: F
authors.initials: F
authors.lastname: Nöthiger
authors.forename: T
authors.initials: T
authors.lastname: Rüed
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001773:Blood Cells / Q000187:drug effects*; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006454:Hemoglobins / Q000032:analysis; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D008937:Mitomycins / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D006454:Hemoglobins; D008937:Mitomycins; D006493:Heparin; D005472:Fluorouracil